503A compounding pharmacy
A 503A compounding pharmacy is a state-licensed pharmacy that prepares customized medications for individual patients in response to a specific prescription, operating under Section 503A of the Federal Food, Drug, and Cosmetic Act.
- Regulated primarily by state boards of pharmacy
- Compounds only from the 503A bulks list, USP monographs, or FDA-approved components
- Requires a patient-specific prescription for every compound
- Ships interstate only where it holds non-resident pharmacy licenses
What does 503A mean in practice?
Section 503A is the part of federal law that lets a traditional pharmacy compound a drug — combine, mix, or alter ingredients — for an identified patient without that drug going through FDA approval. The trade-off is scale: a 503A pharmacy compounds per prescription, patient by patient, and is regulated primarily by its state board of pharmacy rather than directly by the FDA.
For a telehealth business, 503A pharmacies matter because most compounded therapies — hormone preparations, certain peptides, customized dosage forms — are dispensed this way. When a licensed clinician writes a prescription for a specific patient, a 503A pharmacy can fill it, including with compounded formulations that have no commercial equivalent.
Why the 503A bulks list matters
A 503A pharmacy may only compound with bulk drug substances that appear on the FDA’s 503A bulks list, are the subject of a USP monograph, or are components of FDA-approved drugs. Which substances sit on (or off) that list effectively decides what compounded therapies a telehealth program can offer. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) reviews nominated substances and votes on recommendations — which is why PCAC meetings, like the July 2026 peptide votes, move markets.
503A vs 503B: which one does a telehealth program use?
The short answer: usually both, for different jobs. A 503A pharmacy fills patient-specific prescriptions — the model that fits individualized telehealth care. A 503B outsourcing facility manufactures larger batches without patient-specific prescriptions, under full FDA cGMP oversight, and typically supplies clinics and health systems rather than individual mail-order patients.
- 503A: patient-specific prescription required; state-board regulated; per-patient compounding.
- 503B: batch production allowed; FDA-registered and cGMP-inspected; supplies offices and facilities.
- Most DTC telehealth fulfillment runs through 503A pharmacies; clinic-administered programs often source from 503B.
Common pitfalls when building on 503A
Interstate licensing catches teams first: a 503A pharmacy fills for the states where it holds licenses, not the states where you sell. A national program needs a pharmacy network whose non-resident licenses cover every launch state — and routing that sends each prescription to a pharmacy licensed for that patient.
The bulks list moves. Substances get added, rejected, or placed under enforcement discretion, and a formulation that was compoundable in January can be off the menu by summer — the July 2026 peptide votes are the live example. Programs built on compounded therapies need a substitution plan, not just a growth plan.
Finally, 503A pharmacies generally may not compound what is “essentially a copy” of a commercially available FDA-approved drug — the rule at the center of the GLP-1 compounding fights. When a drug shortage ends, so does the legal basis for compounding its copy.
Inside the pharmacy: how a compound gets made
A prescription arrives and maps to a formulation record — the pharmacy’s recipe specifying ingredients, quantities, and process. Compounding happens under USP standards: <795> for non-sterile preparations, <797> for sterile ones (which covers injectables — meaning every GLP-1 and most peptides). Quality checks follow, a beyond-use date is assigned (much shorter than a manufactured drug’s expiration, because compounded preparations aren’t stability-tested at industrial scale), and the preparation is dispensed or shipped to the named patient.
Choosing a 503A partner
The pharmacy relationship is program infrastructure, and diligence has a shape:
| Check | Why it matters |
|---|---|
| Non-resident licenses in your states | Their license map is your coverage map — a gap is a state you can’t serve |
| Sterile compounding capability (USP <797>) | GLP-1s and most peptides are injectables; not every 503A does sterile work |
| API sourcing and certificates of analysis | FDA-registered suppliers with per-lot CoAs are the quality floor |
| Capacity and turnaround | Refill reliability is retention — a backed-up pharmacy is a churn event |
| Inspection and board history | State board records are public; read them before you sign |
Compliance handled, so you can build
Lithos runs the clinicians, pharmacies, and 50-state rules behind your care program — one API.
Frequently asked questions
Is a 503A compounding pharmacy FDA-approved?
No — 503A pharmacies are state-licensed, and compounded drugs are not FDA-approved products. Section 503A exempts them from approval requirements when compounding for an individual patient’s prescription.
Can a 503A pharmacy ship to other states?
Only where it holds a non-resident pharmacy license. A telehealth program shipping nationally needs pharmacy partners licensed in every state it serves.
What can a 503A pharmacy legally compound?
Substances on the FDA’s 503A bulks list, substances with a USP or NF monograph, or components of FDA-approved drugs — prescribed for a specific patient.
Who inspects 503A pharmacies?
Primarily state boards of pharmacy, though the FDA can and does inspect when concerns arise.